BridgeMD
New treatment option for AKI - Acute Kidney Injury
Official title Pharmacokinetics Vancomycin CVVHDF with OXiris Membrane
ClinicalTrials.gov ID: NCT06543940
What this study is testing
What is Vancomycin?
Vancomycin is an investigational medicine, being studied as a potential treatment for aki - acute kidney injury.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is a general pharmacokinetic investigation of vancomycin in patients receiving continuous veno-venous hemodiafiltration (CRRT) with the oXiris membrane. This membrane offers the added benefit of absorbing inflammatory cytokines.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patients aged more than 18 years.
- Admitted to the intensive care unit of Ramathibodi Hospital.
- Under continuous renal replacement therapy (CRRT) with CVVHDF using oXiris filter.
- Received vancomycin at least once after starting CRRT with CVVHDF using oXiris filter.
- who have signed the informed consent document.
You likely can't join if
- Patients with a history of vancomycin allergy.
- Patients expected to die within 24 hours after inclusion in study.
- Patients with circuit clotting occurring more than 2 hours during the blood draw period.
- Patients treated with extracorporeal membrane oxygenation (ECMO).
- Patients with a history of kidney transplantation.
- Pregnant or breastfeeding women.
See the full eligibility criteria
- Patients aged more than 18 years.
- Admitted to the intensive care unit of Ramathibodi Hospital.
- Under continuous renal replacement therapy (CRRT) with CVVHDF using oXiris filter.
- Received vancomycin at least once after starting CRRT with CVVHDF using oXiris filter.
- who have signed the informed consent document.
- Patients with a history of vancomycin allergy.
- Patients expected to die within 24 hours after inclusion in study.
- Patients with circuit clotting occurring more than 2 hours during the blood draw period.
- Patients treated with extracorporeal membrane oxygenation (ECMO).
- Patients with a history of kidney transplantation.
- Pregnant or breastfeeding women.
- Patients who have decided to receive palliative care.
- Patients on hemodialysis or peritoneal dialysis.
The study team makes the final eligibility decision.
Where it's taking place
- Bangkok, Payathi, Thailand
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bangkok, Payathi, Thailand. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.